# Focal Hepatic Steatosis Mimicking a Hilar Tumor With Rapid Resolution After Glycemic Control: A Case Report

**Authors:** Hiroteru Kamimura, Hiroshi Suzuki, Azusa Sone, Makoto Miyazawa, Yuzo Kawata, Yuko Komoro, Yosuke Horii, Takanori Tsujimura, Hirohito Sone, Shuji Terai

PMC · DOI: 10.7759/cureus.102666 · Cureus · 2026-01-30

## TL;DR

A case report shows how focal hepatic steatosis, mistaken for a tumor, resolved after controlling blood sugar levels.

## Contribution

Demonstrates a non-invasive diagnostic approach using metabolic optimization and imaging follow-up for focal hepatic steatosis.

## Key findings

- Focal hepatic steatosis in segment IV mimicked a hilar tumor but resolved after glycemic control.
- Chemical shift MRI supported steatosis, avoiding unnecessary biopsy.
- Lesion disappeared within three months with improved HbA1c levels.

## Abstract

Focal hepatic steatosis can present as a mass-like pseudolesion, particularly in segment IV (S4) adjacent to the hepatic hilum, and may raise concern for perihilar malignancy. We report a 56-year-old woman with severe hyperglycemia (random plasma glucose 564 mg/dL; HbA1c 12.4%) in whom ultrasonography and computed tomography revealed a small hilar S4 lesion suspicious for a perihilar tumor. Magnetic resonance imaging demonstrated a prominent signal drop on opposed-phase chemical shift imaging without diffusion restriction and without biliary ductal abnormality on MR cholangiopancreatography, favoring focal steatosis rather than neoplasm. Based on these findings, we prioritized metabolic optimization with short-interval follow-up rather than immediate biopsy. After intensive glycemic control, HbA1c improved to 6.6%, and the lesion completely disappeared within three months, confirmed sequentially on ultrasonography, contrast-enhanced CT, and MRI. This case highlights a practical strategy: when chemical shift MRI supports focal steatosis and ancillary malignant features are absent, metabolic optimization followed by short-interval follow-up imaging can confirm the diagnosis and avoid unnecessary invasive procedures.

## Linked entities

- **Diseases:** hyperglycemia (MONDO:0002909)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, GAD1 (glutamate decarboxylase 1) [NCBI Gene 2571] {aka CPSQ1, DEE89, GAD, GAD-67, SCP}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, PTPRN (protein tyrosine phosphatase receptor type N) [NCBI Gene 5798] {aka IA-2, IA-2/PTP, IA2, ICA512, R-PTP-N}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, POR (cytochrome p450 oxidoreductase) [NCBI Gene 5447] {aka CPR, CYPOR, P450R}
- **Diseases:** steatotic liver disease (MESH:D008107), inflammatory peribiliary disease (MESH:D007249), biliary abnormality (MESH:D001657), metastasis (MESH:D009362), hyperglycemia (MESH:D006943), dyslipidemia (MESH:D050171), NAFLD (MESH:D065626), Tumor (MESH:D009369), diabetes (MESH:D003920), weight loss (MESH:D015431), polydipsia (MESH:D059606), insulin resistance (MESH:D007333), pseudotumor (MESH:D006104), Hepatic Steatosis (MESH:D005234), biliary ductal abnormality (MESH:D044584), T2DM (MESH:D003924), S4 lesion (MESH:D009059), Hepatic (MESH:D056486), steatotic liver (MESH:D017093), Hilar Tumor (MESH:D018285), Metabolically-dysfunction (MESH:D008659), ketonuria (MESH:D007662)
- **Chemicals:** D-Bil (-), thyroxine (MESH:D013974), lispro (MESH:D061268), K (MESH:D011188), inorganic phosphate (MESH:D010710), P (MESH:D010758), TG (MESH:D013866), Na (MESH:D012964), bilirubin (MESH:D001663), Cr (MESH:D002857), sitagliptin (MESH:D000068900), uric acid (MESH:D014527), Cl (MESH:D002713), triglycerides (MESH:D014280), carbohydrate (MESH:D002241), fatty-acid (MESH:D005227), lipid (MESH:D008055), alcohol (MESH:D000438), triiodothyronine (MESH:D014284), glucose (MESH:D005947), creatinine (MESH:D003404), Ca (MESH:D002118), chloride (MESH:D002712)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950330/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950330/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950330/full.md

---
Source: https://tomesphere.com/paper/PMC12950330